You can buy or sell FOLD and other stocks, options, ETFs, and crypto commission-free!
Amicus Therapeutics, Inc. engages in the discovery, developmen0t, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. Read More The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
Cranbury, New Jersey
52 Week High
52 Week Low
Amicus Therapeutics nabs two patents in U.S.; shares up 4% premarket
The USPTO has issued two new patents to Amicus Therapeutics (NASDAQ:FOLD) directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, to enhance uptake.
Amicus Therapeutics Issued Two U.S. Patents for Pompe Enzyme ATB200
CRANBURY, N.J., March 20, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the United States Patent and Trademark Office has issued two new patents directed to the composition of matter and methods of making ATB200, a unique recombinant human acid alpha-glucosidase (rhGAA) enzyme with optimized carbohydrate structures, particularly mannose-6 phosphate (M6P), to enhance uptake.
Yahoo FinanceMar 15
Edited Transcript of FOLD earnings conference call or presentation 28-Feb-19 1:30pm GMT
Q4 2018 Amicus Therapeutics Inc Earnings Call Cranbury Mar 15, 2019 (Thomson StreetEvents) -- Edited Transcript of Amicus Therapeutics Inc earnings conference call or presentation Thursday, February 28, 2019 at 1:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Bradley L. Campbell Amicus Therapeutics, Inc. - President, COO & D...
Expected May 8, Pre-Market